368 related articles for article (PubMed ID: 33278683)
1. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
3. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
4. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
6. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
7. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
9. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
[TBL] [Abstract][Full Text] [Related]
10. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy.
Xie L; Li J; Wang G; Sang W; Xu M; Li W; Yan J; Li B; Zhang Z; Zhao Q; Yuan Z; Fan Q; Dai Y
J Am Chem Soc; 2022 Jan; 144(2):787-797. PubMed ID: 34985903
[TBL] [Abstract][Full Text] [Related]
11. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
13. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
14. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Wang D; Wang T; Liu J; Yu H; Jiao S; Feng B; Zhou F; Fu Y; Yin Q; Zhang P; Zhang Z; Zhou Z; Li Y
Nano Lett; 2016 Sep; 16(9):5503-13. PubMed ID: 27525587
[TBL] [Abstract][Full Text] [Related]
15. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Juneja VR; McGuire KA; Manguso RT; LaFleur MW; Collins N; Haining WN; Freeman GJ; Sharpe AH
J Exp Med; 2017 Apr; 214(4):895-904. PubMed ID: 28302645
[TBL] [Abstract][Full Text] [Related]
18. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
19. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
[TBL] [Abstract][Full Text] [Related]
20. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle.
Feng ZH; Li ZT; Zhang S; Wang JR; Li ZY; Xu MQ; Li H; Zhang SQ; Wang GX; Liao A; Zhang X
Acta Biomater; 2021 Dec; 136():495-507. PubMed ID: 34619371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
